Edition:
United Kingdom

Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

21.24USD
21 Aug 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$21.24
Open
$21.21
Day's High
$21.24
Day's Low
$21.00
Volume
2,026
Avg. Vol
4,785
52-wk High
$23.45
52-wk Low
$11.30

Latest Key Developments (Source: Significant Developments)

Zealand Pharma H1 Operating Loss Widens To DKK 272.1 Million
Thursday, 15 Aug 2019 

Aug 15 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA DELIVERS STRONG CLINICAL RESULTS DURING THE FIRST HALF OF 2019 AND ACCELERATES COMMERCIAL BUILD-UP IN THE U.S..IN 2019, ZEALAND EXPECTS REVENUE FROM EXISTING LICENSE AGREEMENTS.HOWEVER, SINCE SUCH REVENUE IS UNCERTAIN IN TERMS OF SIZE AND TIMING, ZEALAND DOES NOT GUIDE ON SUCH REVENUE..NET OPERATING EXPENSES IN 2019 ARE NOW EXPECTED TO BE WITHIN DKK 580-600 MILLION, CHANGED FROM PREVIOUS DKK 550-570 MILLION.CHANGE IN GUIDANCE IS MAINLY RELATED TO STRONG CLINICAL PROGRESS RESULTING IN ADDITIONAL SPEND ON ZP7570 AND DASIGLUCAGON CHI PROGRAMS, AND ACCELERATED BUILD-UP IN U.S. TO PREPARE FOR COMMERCIALIZATION OF GLEPAGLUTIDE AND DASIGLUCAGON.H1 REVENUE OF DKK 19.9 MILLION / USD 3.0 MILLION (DKK 24.9 MILLION / USD 3.9 MILLION IN FIRST SIX MONTHS OF 2018).H1 NET OPERATING RESULT OF DKK -272.1 MILLION / USD -41.5 MILLION (DKK -203.5 MILLION / USD -31.8 MILLION IN FIRST SIX MONTHS OF 2018).  Full Article

Zealand Pharma Executive Vice President And CSO Andrew Parker To Step Down
Monday, 29 Jul 2019 

July 29 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA ANNOUNCES CHANGE IN CORPORATE MANAGEMENT.ANDREW PARKER HAS ACCEPTED A TOP EXECUTIVE LEADERSHIP POSITION IN A NON-COMPETING BIOTECHNOLOGY COMPANY OUTSIDE DENMARK.HE WILL REMAIN IN HIS ROLE WITH ZEALAND PHARMA UNTIL AUGUST 31, 2019.PROCESS TO HIRE A NEW CHIEF SCIENTIFIC OFFICER IS WELL UNDERWAY.RIE SCHULTZ HANSEN, VICE PRESIDENT OF RESEARCH AT ZEALAND PHARMA, HAS BEEN APPOINTED AS INTERIM DEPARTMENT LEAD UNTIL NEW PERMANENT CSO IS IN PLACE.  Full Article

Zealand Pharma Total Proceeds From Capital Increase Amount To DKK 9.0 Mln
Friday, 14 Jun 2019 

June 14 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA INCREASES ITS SHARE CAPITAL AS A CONSEQUENCE OF EXERCISE OF EMPLOYEE WARRANTS.INCREASED ITS SHARE CAPITAL BY A NOMINAL AMOUNT OF DKK 89,315 DIVIDED INTO 89,315 NEW SHARES.EXERCISE PRICE WAS DKK 101.20 PER SHARE.TOTAL PROCEEDS TO ZEALAND FROM CAPITAL INCREASE AMOUNT TO DKK 9,038,678.00.  Full Article

Beta Bionics And Zealand Pharma Announce Superior Glycemic Control In Phase 2 Trial Of iLet
Thursday, 6 Jun 2019 

June 6 (Reuters) - Zealand Pharma A/S ::REG-BETA BIONICS AND ZEALAND PHARMA ANNOUNCE SUPERIOR GLYCEMIC CONTROL IN PHASE 2 HOME-USE CLINICAL TRIAL TESTING THE ILET™ BIONIC PANCREAS USING DASIGLUCAGION.FIRST HOME-USE TRIAL OF ILET BIONIC PANCREAS SYSTEM USING PRE-FILLED CARTRIDGES OF DASIGLUCAGON COMPATIBLE WITH ILET HAS BEEN SUCCESSFULLY COMPLETED.ILET THERAPY WAS INITIALIZED WITH BODY WEIGHT ONLY, WITH NO DEVICE TRAINING PERIODS, AND WITH NO PHYSICIAN INTERVENTION TO OPTIMIZE THERAPY.PRELIMINARY STUDY RESULTS REVEAL SUPERIOR BLOOD GLUCOSE CONTROL DURING STUDY PERIOD THAT USED BIHORMONAL CONFIGURATION OF ILET WITH DASIGLUCAGON COMPARED TO PERIOD THAT USED INSULIN-ONLY CONFIGURATION.  Full Article

Zealand Pharma Q1 Net Operating Loss Widens To DKK 135.8 Million
Thursday, 16 May 2019 

May 16 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA INITIATES SEVERAL PHASE 3 STUDIES AND GROWS CASH POSITION IN THE FIRST QUARTER OF 2019.IN 2019, EXPECTS REVENUE FROM NEW POTENTIAL PARTNERSHIP AGREEMENTS AND FROM MILESTONES FROM EXISTING LICENSE AGREEMENTS.NET OPERATING EXPENSES IN 2019 ARE EXPECTED TO BE WITHIN DKK 550-570 MILLION.Q1 NET OPERATING LOSS DKK 135.8 MILLION VERSUS LOSS DKK 88.5 MILLION YEAR AGO.Q1 REVENUE DKK 0.0 MILLION VERSUS DKK 9.7 MILLION YEAR AGO.  Full Article

Zealand Pharma Achieves Endpoints In Confirmatory Phase 3 Trial With Dasiglucagon
Tuesday, 14 May 2019 

May 14 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA ACHIEVES PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN CONFIRMATORY PHASE 3 TRIAL WITH DASIGLUCAGON FOR SEVERE HYPOGLYCEMIA.PRIMARY AND ALL KEY SECONDARY ENDPOINTS SUCCESSFULLY ACHIEVED IN TRIAL.MEDIAN TIME TO RECOVERY FROM LOW BLOOD GLUCOSE WAS 10 MINUTES FOLLOWING DASIGLUCAGON INJECTION ADMINISTERED VIA HYPOPAL(®) RESCUE PEN.THIRD CONSECUTIVE PHASE 3 TRIAL WITH POSITIVE RESULTS FOR DASIGLUCAGON.SUBMISSION OF NEW DRUG APPLICATION (NDA) TO U.S. FDA IS NOW EXPECTED EARLY 2020..FINAL PHASE 3 TRIAL THAT WILL COMPLETE OUR NDA APPLICATION IS IN PEDIATRIC DIABETES PATIENTS AND IS STILL ONGOING.NO SAFETY CONCERNS WERE RAISED FOR DASIGLUCAGON WITHIN TRIAL.  Full Article

Zealand Pharma And Alexion Announce Collaboration
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Zealand Pharma A/S ::REG-ALEXION AND ZEALAND PHARMA ANNOUNCE COLLABORATION TO DISCOVER AND DEVELOP PEPTIDE THERAPIES FOR COMPLEMENT-MEDIATED DISEASES.ZEALAND PHARMA TO RECEIVE UPFRONT PAYMENT OF $25 MILLION AND EQUITY INVESTMENT OF $15 MILLION.ZEALAND PHARMA WITH POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT AND ROYALTY PAYMENTS.AGREEMENT PROVIDES POTENTIAL FOR DEVELOPMENT-RELATED MILESTONES OF UP TO $115 MILLION.AGREEMENT PROVIDES AS WELL AS UP TO $495 MILLION IN SALES-RELATED MILESTONES AND POTENTIAL FOR HIGH SINGLE- TO LOW DOUBLE-DIGIT ROYALTY PAYMENTS.  Full Article

Zealand Pharma: Britt Meelby Jensen To Resign From Position As President And CEO
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA ANNOUNCES CHANGE IN EXECUTIVE MANAGEMENT.REG-ZEALAND PHARMA ANNOUNCES CHANGE IN EXECUTIVE MANAGEMENT.BRITT MEELBY JENSEN HAS TODAY DELIVERED HER NOTICE TO RESIGN FROM HER POSITION AS PRESIDENT AND CEO.WILL REMAIN IN HER POSITION WITH ZEALAND PHARMA UNTIL FURTHER NOTICE..PROCESS OF FINDING A REPLACEMENT FOR BRITT MEELBY JENSEN WILL COMMENCE IMMEDIATELY..  Full Article

Zealand Pharma Achieves Primary And Key Secondary Endpoints In Pivotal Phase 3 Trial With Dasiglucagon For Severe Hypoglycemia
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Zealand Pharma A/S ::ZEALAND PHARMA ACHIEVES PRIMARY AND KEY SECONDARY ENDPOINTS IN PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR SEVERE HYPOGLYCEMIA.ZEALAND PHARMA A/S - 99% OF PATIENTS ON DASIGLUCAGON RECOVERED FROM LOW BLOOD GLUCOSE WITHIN 15 MINUTES.ZEALAND PHARMA A/S - OVERALL, NO SAFETY CONCERNS WERE RAISED FOR DASIGLUCAGON WITHIN THE TRIAL.ZEALAND PHARMA A/S - NAUSEA AND VOMITING WERE REPORTED WITH SIMILAR NUMBERS FOR DASIGLUCAGON AND GLUCAGEN.ZEALAND PHARMA A/S - WILL SOON INITIATE A PHASE 3 TRIAL IN PEDIATRIC DIABETES PATIENTS, WHICH IS EXPECTED TO COMPLETE IN MID-2019.  Full Article

Zealand Q1 Net Sales Of Soliqua 100/33 And Lyxumia/Adlyxin At EUR 14.5 Mln
Friday, 27 Apr 2018 

April 27 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND ANNOUNCES NET SALES OF SOLIQUA® 100/33 AND LYXUMIA®/ADLYXIN® FOR THE FIRST QUARTER OF 2018.NET SALES OF SOLIQUA(®) 100/33 AND LYXUMIA(®)/ADLYXIN(®) OF EUR 14.5 MILLION/USD 17.9 MILLION IN Q1 2018.  Full Article